EON: Phase II trial of etigilimab (MPH313) in combination with nivolumab in patients with recurrent platinum-resistant clear cell ovarian cancer.
Ji Y. Son(California State University Los Angeles), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Travis T. Sims(The University of Texas MD Anderson Cancer Center), Emily Hinchcliff(The University of Texas MD Anderson Cancer Center), William F. Feely(Memorial Sloan Kettering Cancer Center), Padmanee Sharma(The University of Texas MD Anderson Cancer Center), R. Tyler Hillman(The University of Texas MD Anderson Cancer Center), Sreyashi Basu(The University of Texas MD Anderson Cancer Center), Adzoa Ekue(CTI BioPharma (United Kingdom)), Jeffrey How(The University of Texas MD Anderson Cancer Center), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Nancy Tran(The University of Texas MD Anderson Cancer Center), Nicole D. Fleming(The University of Texas MD Anderson Cancer Center), Shuqi Wang(The University of Texas MD Anderson Cancer Center), Anil K. Sood(The University of Texas MD Anderson Cancer Center), Joseph Davis(Truman Bodden Law School), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Yuwei Zhang(The University of Texas MD Anderson Cancer Center), Ying Yuan(The University of Texas MD Anderson Cancer Center)
Cited by 1
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
The Next Decade of Immune Checkpoint Therapy
|Cancer Discovery|2021|739